Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants

Key Inclusion Criteria: 1. Hospitalization for COVID-19 infection 2. Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by polymerase chain reaction (PCR) 3. Participant requires supplemental oxygen for pulmonary distress related to COVID-19 infection, and has been on supplemental oxygen for no more than 96 hours from time of screening Key Exclusion Criteria: 1. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction 2. On a Bruton's tyrosine kinase (BTK) inhibitor 3. Planned or concurrent use of a host modifiers/immune-based therapies or anti-CD20 monoclonal antibody treatment 4. Participants with prior of current hematologic malignancy or solid tumor malignancy with treatment within 6 months prior to study entry NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.